Magnus Medical announced today that it treated the first patients in the open-label optimization clinical trial for its Saint technology. The OLO trial evaluates the effectiveness of Saint technology for the treatment of major depressive disorder (MDD). The platform delivers individualized, rapid-acting, non-invasive neurostimulation. Saint treats adults who fail to achieve satisfactory improvement from prior antidepressant […]
Magnus Medical
FDA clears neuromod system for treating depression from Magnus Medical
Magnus Medical announced today that it received FDA 510(k) clearance for its Saint neuromodulation system. Burlingame, California-based Magnus designed Saint for the treatment of major depressive disorder (MDD). It treats adults who fail to achieve satisfactory improvement from prior antidepressant medications in the current episode. The individualized, rapid-acting, non-invasive neurostimulation platform demonstrated the potential to […]
FDA grants breakthrough nod to Magnus Medical’s neurostim treatment for depression
Magnus Medical announced today that it received FDA breakthrough device designation for its neurostimulation technology and raised $25 million. Burlingame, California-based Magnus designed its individualized, rapid-acting, non-invasive neurostimulation platform to treat major depressive disorder (MDD) for people who have not improved sufficiently from antidepressant medication or other treatments. Magnus based its system on SAINT technology, […]